NSCLC harboring EGFR L858R or exon 19 deletion mutations is sensitive to the EGFR-tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.